Gain-of-function mutations in the catalytic domain of <i>DOT1L</i> promote lung cancer malignant phenotypes via the MAPK/ERK signaling pathway.

The combination of SGC0946 and binimetinib retarded tumor growth and reduced the tumor burden, and the effect was highly significant compared to the single treatments ( Fig. 8C ).

also in 132,142 other papers